A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy

The aim of this systematic review and meta-analysis is to evaluate available prevalence and viral sequencing data representing chronic hepatitis B (CHB) infection in Kenya. More than 20% of the global disease burden from CHB is in Africa, however there is minimal high quality seroprevalence data from individual countries and little viral sequencing data available to represent the continent. We undertook a systematic review of the prevalence and genetic data available for hepatitis B virus (HBV) in Kenya using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 checklist. We identified 23 studies reporting HBV prevalence and 8 studies that included HBV genetic data published in English between January 2000 and December 2021. We assessed study quality using the Joanna Briggs Institute critical appraisal checklist. Due to study heterogeneity, we divided the studies to represent low, moderate, high and very high-risk for HBV infection, identifying 8, 7, 5 and 3 studies in these groups, respectively. We calculated pooled HBV prevalence within each group and evaluated available sequencing data. Pooled HBV prevalence was 3.4% (95% CI 2.7–4.2%), 6.1% (95% CI 5.1–7.4%), 6.2% (95% CI 4.64–8.2) and 29.2% (95% CI 12.2–55.1), respectively. Study quality was overall low; only three studies detailed sample size calculation and 17/23 studies were cross sectional. Eight studies included genetic information on HBV, with two undertaking whole genome sequencing. Genotype A accounted for 92% of infections. Other genotypes included genotype D (6%), D/E recombinants (1%) or mixed populations (1%). Drug resistance mutations were reported by two studies. There is an urgent need for more high quality seroprevalence and genetic data to represent HBV in Kenya to underpin improved HBV screening, treatment and prevention in order to support progress towards elimination targets.

[1]  M. Yotebieng,et al.  Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study , 2021, The Lancet. Global health.

[2]  M. Robb,et al.  Hepatitis and tuberculosis testing are much less common than HIV testing among adults in Kisumu, Kenya: results from a cross-sectional assessment , 2021, BMC Public Health.

[3]  Jasmit S. Shah,et al.  Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults , 2021, PloS one.

[4]  G. Gachara,et al.  Seroprevalence and genotypic characterization of HBV among low risk voluntary blood donors in Nairobi, Kenya , 2020, Virology Journal.

[5]  G. Gitao,et al.  Seroprevalence and Risk Factors for Hepatitis B Virus Infection in Adolescent Blood Donors within Selected Counties of Western Kenya , 2020, BioMed research international.

[6]  L. McKinnon,et al.  Characterization of occult hepatitis B in high-risk populations in Kenya , 2020, PloS one.

[7]  M. Ansari,et al.  Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences , 2019, bioRxiv.

[8]  J. Oundo,et al.  Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya , 2019, The Pan African medical journal.

[9]  O. Gascuel,et al.  NGPhylogeny.fr: new generation phylogenetic services for non-specialists , 2019, Nucleic Acids Res..

[10]  S. Lowther,et al.  Prevalence of hepatitis B virus infection and uptake of hepatitis B vaccine among healthcare workers, Makueni County, Kenya 2017. , 2018, Journal of public health.

[11]  J. McKeating,et al.  Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood , 2018, Gastroenterology.

[12]  K. Durth,et al.  Prisma , 2018, Homiletische Monatshefte.

[13]  J. Wylie,et al.  Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities , 2018, Southern African journal of HIV medicine.

[14]  B. Guyah,et al.  Seroprevalence and determinants of transfusion transmissible infections among voluntary blood donors in Homabay, Kisumu and Siaya counties in western Kenya , 2018, BMC Research Notes.

[15]  C. Thio,et al.  Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052 , 2017, Journal of acquired immune deficiency syndromes.

[16]  C. Combet,et al.  How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? , 2017, Journal of hepatology.

[17]  E. Oyugi,et al.  Transfusion Transmissible Infections Among Walk-In Blood Donors at Kisumu Regional Blood Transfusion Centre, Kisumu County, Kenya, 2015 , 2017, Laboratory medicine.

[18]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[19]  K. Marsh,et al.  Hepatitis B virus infection as a neglected tropical disease , 2017, bioRxiv.

[20]  J. Omolo,et al.  Sero-prevalence for Hepatitis B virus among pregnant women attending antenatal clinic in Juba Teaching Hospital, Republic of South Sudan , 2017, The Pan African medical journal.

[21]  S. Graham,et al.  Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus-1 Negative Men Who Have Sex With Men in Kenya , 2016, Open forum infectious diseases.

[22]  Z. Ng'ang'a,et al.  Prevalence, awareness and risk factors associated with Hepatitis B infection among pregnant women attending the antenatal clinic at Mbagathi District Hospital in Nairobi, Kenya , 2016, The Pan African medical journal.

[23]  J. Montgomery,et al.  Prevalence of Hepatitis B Virus Infection in Kenya, 2007. , 2016, The American journal of tropical medicine and hygiene.

[24]  N. Budambula,et al.  Hepatitis B infection is highly prevalent among patients presenting with jaundice in Kenya , 2016, BMC Infectious Diseases.

[25]  D. Reynders,et al.  Nosocomial outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South Africa: Epidemiological investigation and measures to prevent further transmission , 2015, Pediatric blood & cancer.

[26]  N. Budambula,et al.  Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya , 2015, BMC Infectious Diseases.

[27]  R. Lihana,et al.  Characterization of HBV Among HBV/HIV-1 Co-Infected Injecting Drug Users from Mombasa, Kenya. , 2015, Current HIV research.

[28]  Y. Karino,et al.  Risk factors for long‐term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults , 2014, Hepatology.

[29]  R. Chauhan,et al.  Genotyping and molecular characterization of hepatitis B virus in liver disease patients in Kenya. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[30]  A. Nyamache,et al.  Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya , 2013, BMC Research Notes.

[31]  N. Budambula,et al.  Hepatitis B virus subgenotype A1, occurrence of subgenotype D4, and S gene mutations among voluntary blood donors in Kenya , 2013, Virus Genes.

[32]  K. Mandaliya,et al.  Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy , 2013, PloS one.

[33]  F. Okoth,et al.  SEROPREVALENCE OF HAV, HBV, HCV, AND HEV AMONG ACUTE HEPATITIS PATIENTS AT KENYATTA NATIONAL HOSPITAL IN NAIROBI, KENYA. , 2012, East African medical journal.

[34]  G. John-Stewart,et al.  HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya , 2011, Journal of viral hepatitis.

[35]  J. Kao,et al.  The clinical implications of hepatitis B virus genotype: Recent advances , 2011, Journal of gastroenterology and hepatology.

[36]  Xinwen Chen,et al.  Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. , 2010, The Journal of general virology.

[37]  M. Nelson,et al.  HIV, hepatitis B and hepatitis C coinfection in Kenya , 2008, AIDS.

[38]  Z. Meng,et al.  The Amino Acid Residues at Positions 120 to 123 Are Crucial for the Antigenicity of Hepatitis B Surface Antigen , 2007, Journal of Clinical Microbiology.

[39]  A. Otedo HBV, HIV co-infection at Kisumu District Hospital, Kenya. , 2005, East African medical journal.

[40]  W. Hardison,et al.  Prevalence of hepatitis A, B, C and human immunodeficiency virus seropositivity among patients with acute icteric hepatitis at the Kenyatta National Hospital, Nairobi. , 2004, East African medical journal.

[41]  D. S. Dane,et al.  A sensitive single reverse passive haemagglutination test for detecting both HBsAg and anti-HBs. , 1979, Journal of clinical pathology.

[42]  Melbourne Victoria A Ministry of Health , 1917, Nature.

[43]  K. Mutai,et al.  Genotypes of HBV and HCV among HIV-1 co-infected individuals in Ngong Sub-County, Kenya , 2016 .

[44]  J. Kiarie,et al.  Prevalence and risk factors of previous or active Hepatitis B infection among HIV-1 discordant heterosexual couples , 2015 .